Weekly Recap: Top 10 U.S. Funding Rounds – Biotech Dominates as Year-end Approaches
Explore the top 10 announced funding rounds in the U.S. for the week, featuring prominent biotech raises and a notable investment in the space sector. Check out the details of each funding round, including the significant investments in companies like Tome Biosciences, Bicara Therapeutics, True Anomaly, and more.
As the year-end approaches, the U.S. investment landscape remains vibrant, witnessing substantial funding rounds across various sectors. Biotech steals the spotlight this week with groundbreaking raises, while the space sector and artificial intelligence also secure noteworthy investments. Here’s a rundown of the top 10 announced funding rounds:
Tome Biosciences – $213M (Biotech):
Watertown, Massachusetts-based Tome Biosciences secured a remarkable $213 million in a combination Series A and B funding. The biotech company, known for its “molecular surgery” technology, plans to develop gene therapies using sophisticated analytics. Investors include Andreessen Horowitz Bio + Health and Arch Venture Partners.
Bicara Therapeutics – $165M (Biotech):
Boston-based Bicara Therapeutics returns to the list with a $165 million Series C co-led by Braidwell and TPG. Specializing in biologics for tumor treatment, Bicara Therapeutics has already made strides in clinical trials for head and neck cancer. The latest funding adds to the $108 million raised in a Series B earlier this year.
True Anomaly – $100M (Space):
True Anomaly, based in Centennial, Colorado, secured $100 million in funding led by Riot Ventures. Specializing in space security and readiness, the startup’s Jackal autonomous orbital vehicles are set to launch aboard SpaceX’s Transporter-10 mission. The funding boosts True Anomaly’s efforts in helping governments and commercial entities monitor threats to space assets.
Totus Medicines – $66M (Biotech):
Emeryville, California-based Totus Medicines raised $66 million in a Series B financing round led by DCVC Bio. The company focuses on small molecule drug discovery and development, utilizing covalent libraries and AI tools. Totus Medicines has raised a total of $106 million to date.
Essential AI – $57M (Artificial Intelligence):
San Francisco-based Essential AI secured $56.5 million in new funding, with March Capital leading the round. Notable investors include Advanced Micro Devices, Google, and Nvidia. Essential AI aims to automate corporate tasks using AI, and its technology, known as the “Enterprise Brain,” has garnered attention in the AI space.
Deep Apple Therapeutics – $52M (Biotech):
New York-based Deep Apple Therapeutics raised a significant $52 million in its Series A round led by life sciences venture capital firm Apple Tree Partners. The biotech firm focuses on developing small molecule therapeutics through screening AI-generated virtual libraries.
Calyxo – $50M (Medical Device):
Pleasanton, California-based Calyxo closed a $50 million Series D led by Avidity Partners. The medical device startup, founded in 2016, has raised over $97 million. Calyxo aims to advance its innovative medical solutions with the latest funding.
Parse Biosciences – $50M (Biotech):
Seattle-based Parse Biosciences raised $50 million in a Series C, a mix of equity and debt. The company, specializing in scalable single-cell sequencing solutions, received the equity portion from undisclosed investors, with Horizon Technology Finance providing the debt facility. Parse Biosciences has raised a total of $100 million.
Stay tuned for more insights into the dynamic world of U.S. funding rounds, and don’t miss out on the latest trends shaping various industries.
